4 news items
Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
CRBU
DTIL
TGTX
13 May 24
, without limitation, statements regarding the clinical development and expected safety, efficacy and benefit of our and our partners' product candidates
Caribou Biosciences Expands Clinical Development Of CB-010 With FDA Clearance Of IND In Lupus
CRBU
4 Apr 24
to initiate by YE 2024 -- -- Driven by encouraging initial safety and efficacy in the ongoing ANTLER trial for r/r B-NHL, CB-010
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
CRBU
4 Apr 24
-- -- Driven by encouraging initial safety and efficacy in the ongoing ANTLER trial for r/r B-NHL, CB-010 clinical
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
CRBU
DTIL
TGTX
27 Mar 24
efficacy and safety data at the 2023 American Association for the Study of Liver Diseases Annual Meeting. The data demonstrated strong proof of concept
- Prev
- 1
- Next